Searched for
ARI ALTSTEDTER
All the Covid-19 symptoms you didn’t know aboutCovid is now emerging as a pathogen capable of harming in a myriad of unexpected, and sometimes lethal, ways.- FDA lifts curbs on Indian maker of malaria drug touted by Donald Trump as a Covid counterHydroxychloroquine is being snapped up by medical systems at more than twice the typical pace as U.S. hospitals seek to build large invento...
- India to spend $1.3 billion to boost pharmaceutical productionIndia will set up the fund to encourage companies to manufacture pharmaceutical ingredients domestically.
- Shock court order threatens legacy of Tata’s legendary dealmakerThe turmoil couldn’t have hit at a worse time for the $110 billion conglomerate.
- New FDA warning letters show India’s drugmakers still in troubleThe US FDA said it had found similar quality control lapses at Lupin’s two other sites too.
- ‘Karma’ catches up with Ranbaxy's Malvinder and Shivinder SinghAs India cleans up one of the world’s worst bad-loan mess, govt is cracking down on defaulting borrowers.
- Amazon.com nears deal for up to 10% of Future RetailIndia’s No. 2 retailer by turnover, Future is seeking a valuation of about $281 mn from Amazon for 10% stake.
- Apollo Hospitals seeks investor, asset sales to cut debtThe aim is to reduce the Apollo shares pledged by the family as collateral to lenders.
- China's war on healthcare costs lures India's biggest drugmakerShanghvi believes market watchers are underestimating the potential in China for India’s largest drugmaker.
- Spiced buttermilk? Coca-Cola turns to grandmas' recipes in IndiaIn India, its hunt for alternatives has led it to tap into a rich vein of “ethnic drinks”.
- Asia's richest man Mukesh Ambani faces data snag as he prepares for Amazon fightAmbani wants to marry the might of 9,900-plus retail stores and 280-million telecom user base.
- Yes Bank's Rana Kapoor falls foul of bad-debt battleKapoor’s removal shows how far the RBI is preparing to go to root out a system-wide legacy of shoddy lending.
- Drugmaker Strides eyes sale as endgame after business ramps upThe drugmaker’s current market capitalization stands at around $940 million.
- India's plan to reduce medicine prices faces industry pushbackThe Draft Pharmaceutical Policy has made no progress since opposition emerged from the industry and among some government agencies.
- Billionaire Dilip Shanghvi offers mea culpa after Sun Pharma lossSun was tipped into a loss this quarter after it agreed to pay plaintiffs including Canadian rival Apotex to settle a lawsuit over sleep-di...
- $14 billion loss in 2 years for Indian tycoon shows pharma in real bad shapeThe founder of Sun Pharma has seen his net worth fall to $11.1 billion on Bloomberg Index.
- India sets rules to push struggling banks to combine with rivalsBanks where capital adequacy ratio falls below the RBI’s threshold may see the firm being merged, or wound up, according to the document.
- Lupin CFO says $1 billion M&A warchest may be just the startAs of September, the company had about $152 million in cash, and in its most recent earnings conference call said it had about $810 million...
- India's pharma barons are reporting delays in digitizing labsThe Indian pharmaceutical industry’s explosive growth over the past decade has made the nation host to the most FDA-approved plants outside...
- Carry traders lose on Federal Reserve’s talk of tapering QEDeutsche Bank’s G10 FX Carry Basket index fell 3.3% last month, the biggest decline since May 2012, reducing its gain this year to 1.6%.
Load More
